Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 8/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18693933 | 0.88 | CFTR (0.39) | CFTRKDM4EALDH1A1HSD17B10KDM5A | |
| SCHEMBL18694394 | 0.82 | CFTR (0.53) | CFTRKDM4EALDH1A1HSD17B10NR3C1 | |
| SCHEMBL18694643 | 0.80 | CFTR (0.47) | CFTRKDM4EALDH1A1HSD17B10NR3C1 | |
| SCHEMBL18694178 | 0.80 | CFTR (0.49) | CFTRKDM4EALDH1A1HSD17B10NR3C1 | |
| SCHEMBL18694283 | 0.79 | CFTR (0.46) | CFTRKDM4EALDH1A1HSD17B10NR3C1 | |
| SCHEMBL18693594 | 0.79 | CFTR (0.48) | CFTRKDM4EALDH1A1HSD17B10KDM5A | |
| SCHEMBL18694023 | 0.78 | CFTR (0.49) | CFTRKDM4EALDH1A1HSD17B10KDM5A | |
| SCHEMBL18694535 | 0.78 | CFTR (0.49) | CFTRKDM4EALDH1A1HSD17B10NR3C1 | |
| SCHEMBL18692209 | 0.77 | CFTR (0.52) | CFTRNR3C1 | |
| SCHEMBL18694386 | 0.77 | CFTR (0.47) | CFTRKDM4EALDH1A1HSD17B10NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796711-B2 | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use | ABBVIE S.Á.R.L. (LU) | 2017-10-24 | — | — | US | claimed |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-04-13 | — | — | US | claimed |
| US-10130622-B2 | Compounds for treatment of cystic fibrosis | ABBVIE S.Á.R.L. (LU) | 2018-11-20 | — | — | US | disclosed |
| US-9796711-B2 | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use | ABBVIE S.Á.R.L. (LU) | 2017-10-24 | — | — | US | disclosed |
| US-20170100386-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | ABBVIE S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | CFTR, CHRM3, P2RY1 | CFTR 1/4885KDM4E 4749/4885ALDH1A1 1509/4885 |
| US-10130622-B2 | Compounds for treatment of cystic fibrosis | CFTR, CLCN2, SLC26A4 | CFTR 1/4885KDM4E 3964/4885ALDH1A1 3503/4885 |
| US-20170100386-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | CFTR, CLCN2, SLC26A4 | CFTR 1/4885KDM4E 3680/4885ALDH1A1 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.